Bristol-Myers Squibb Co
featured
Take a look at some of Wednesday midday movers:
» Read More
More
-
Baxter International Inc. fell$. 30 or. 4 percent, to $70.46. Bristol-Myers Squibb Co. rose$. 45 or 1.1 percent, to $40.94. Hospira fell$. 39 or 1.1 percent, to $34.23.
-
Baxter International Inc. fell$. 03 or percent, to $70.74. Bristol-Myers Squibb Co. rose$. 24 or. 6 percent, to $40.73. Hospira fell$. 19 or. 5 percent, to $34.43.
-
Baxter International Inc. fell$. 34 or. 5 percent, to $70.42. Bristol-Myers Squibb Co. rose$. 11 or. 3 percent, to $40.60. Hospira fell$. 19 or. 6 percent, to $34.43.
-
Baxter International Inc. fell$. 23 or. 3 percent, to $70.76. Bristol-Myers Squibb Co. rose$. 56 or 1.4 percent, to $40.49. Hospira rose$. 07 or. 2 percent, to $34.62.
-
Baxter International Inc. fell$. 30 or. 4 percent, to $70.69. Bristol-Myers Squibb Co. rose$. 22 or. 6 percent, to $40.15. Hospira rose$. 04 or. 1 percent, to $34.59.
-
Baxter International Inc. rose$. 03 or percent, to $71.02. Bristol-Myers Squibb Co. rose$. 25 or. 6 percent, to $40.18. Hospira fell$. 02 or. 1 percent, to $34.53.
-
Baxter International Inc. fell$. 28 or. 4 percent, to $70.99. Bristol-Myers Squibb Co. rose$. 25 or. 6 percent, to $39.93. Hospira rose$. 95 or 2.8 percent, to $34.55.
-
Baxter International Inc. rose$. 02 or percent, to $71.29. Bristol-Myers Squibb Co. rose$. 13 or. 3 percent, to $39.81. Hospira rose$. 75 or 2.2 percent, to $34.35.
-
Baxter International Inc. fell$. 07 or. 1 percent, to $71.20. Bristol-Myers Squibb Co. fell$. 22 or. 6 percent, to $39.46. Hospira rose$. 30 or. 9 percent, to $33.90.
-
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
-
May 9- Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.
-
Baxter International Inc. rose $2.69 or 3.9 percent, to $71.27. Bristol-Myers Squibb Co. fell$. 34 or. 8 percent, to $39.68. Hospira rose$. 79 or 2.4 percent, to $33.60.
-
After approvals last year from the FDA for 39 novel medicines- a record only beaten in 1996- the healthy pace has continued into 2013.. And drugmakers are getting further help from a new FDA program to accelerate life-saving therapies designated as a "breakthrough," opening to door to earlier approval based on quicker studies, where clinical data is compelling.
-
Baxter International Inc. rose $2.50 or 3.6 percent, to $71.08. Bristol-Myers Squibb Co. fell$. 31 or. 8 percent, to $39.72. Hospira rose$. 32 or 1.0 percent, to $33.13.
-
Baxter International Inc. rose $1.38 or 2.0 percent, to $69.96. Bristol-Myers Squibb Co. fell$. 08 or. 2 percent, to $39.95. Hospira rose$. 12 or. 4 percent, to $32.93.
-
Baxter International Inc. fell $1.73 or 2.5 percent, to $68.58. Hospira rose$. 15 or. 5 percent, to $32.81. Johnson& Johnson rose$. 85 or 1.0 percent, to $85.53.
-
Baxter International Inc. fell $2.47 or 3.5 percent, to $67.84. Bristol-Myers Squibb Co. fell$. 07 or. 2 percent, to $39.95. Hospira rose$. 11 or. 3 percent, to $32.77.
-
Baxter International Inc. fell $2.29 or 3.2 percent, to $68.03. Bristol-Myers Squibb Co. rose$. 09 or. 2 percent, to $40.11. Hospira fell$. 03 or. 1 percent, to $32.63.
-
FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
*Aiming to win bigger slice of growing market* Lilly currently No.4 in $40 bln diabetes market* Lilly says mainly addressing GPs, not specialists By Ludwig Burger and Frank Siebelt. FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.